Novavax investigational COVID-19 vaccine (NVX-CoV2373)

COVID-19 Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
COVID-19
 
Authorized*
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
COVID-19
Status
 
Authorized*
Technology
Matrix-M™ adjuvant

About the candidate

NVX-CoV2373 is a protein-based vaccine targeting SARS-CoV-2, the virus that causes COVID-19. Recombinant technology is used to create vaccine protein antigens, which are arranged around a nanoparticle core and then formulated with Matrix-M™ adjuvant to create the ready-to-use NVX-CoV2373 vaccine. Recombinant technology is used to create vaccine nanoparticles, which are then mixed with Matrix-M™ adjuvant to create the ready-to-use NVX-CoV2373 vaccine. NVX-CoV2373 is still under investigation in the United States and is not authorized for use. For Global authorizations, please refer to the global vaccine authorization/approval map.

NVX-CoV2373 vaccine design

  • 1

    SARS-CoV-2 spike protein gene inserted into insect virus

    The full-length, stabilized spike gene is engineered into baculovirus.

    Baculovirus.Modified spike protein gene. Viral genome. SARS-CoV-2.
  • 2

    Sf9 cells infected

    Recombinant baculovirus infects moth cells in the S. frugiperda (Sf9) expression system.

    Sf9 cell.
  • 3

    Spike gene enters Sf9 cell nucleus

    Spike DNA is transcribed.

    Spike protein gene. Nucleus. mRNA.
  • 4

    Sf9 cells produce spike proteins

    Spike proteins are expressed in their native trimer conformation.

    mRNA. Translation and glycosylation. Spike protein trimers.
  • 5

    Nanoparticle formation

    Spike protein trimers are harvested. Vaccine nanoparticles assemble as spike protein trimers arranged around a Polysorbate 80 (PS80) core.

    PS80 core.
  • 6

    Final vaccine

    Vaccine nanoparticles are mixed with Matrix-MTM adjuvant to create ready-to-use NVX-CoV2373 vaccine.

    Matrix-M adjuvant.

Infographic displaying the NVX-CoV2373 vaccine design

Why it matters

COVID-19 continues to evolve around the world and is responsible for millions of deaths.1 Our NVX-CoV2373 vaccine candidate has been shown to produce robust, functional immune responses in diverse clinical trial populations.

Vaccines produced using Novavax' technology are stable at standard refrigeration temperatures, enabling NVX-CoV2373 to reach people around the world.

*Authorized for use in several countries.
  1. COVID-19 situation update worldwide, as of week 21, updated 3 June 2021. ECDC. Available at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases [Accessed 3 Sept 2021].